Array sues AZ over royalties for cancer drug selumetinib

Array BioPharma is suing AstraZeneca (AZ), accusing the pharmaceutical company of refusing to pay required royalties for selumetinib after entering into an $8.5 billion collaboration with Merck & Co. Selumetinib, discovered by Boulder, Colorado-based Array, inhibits the activity of an enzyme involved in cell growth and metabolism. Array said the 2003 agreement allowed AZ to use selumetinib in research to fight cancer, and provided for a 12% royalty on sums that AZ might receive from sub-licensees such as that with Merck. Both companies agreed to have the disputes of the agreement decided by New York courts.

Click here to go to the full article

Are you ready to explore new ideas?

Learn the many ways TRM Oncology can support you and your valued stakeholders.

All Fields Required